Prostate cancer therapy personalization via multi-modal deep learning on randomized phase iii clinical trials

HIGHLIGHTS

• who: Andre Esteva from the Published in partnership with Seoul National University Bundang Hospital have published the research: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials, in the Journal: (JOURNAL) of 19/05/2022
• what: The authors demonstrate that a multimodal AI (MMAI) system can be used to address an unmet need for accessible and scalable prognostication in localized prostate cancer. This trial had one of the lower event rates and shortest follow-up times compared to the remaining trials, and all patients received hormone therapy. The authors . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.